Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luvometinib in Pediatric Refractory/Recurrent Langerhans Cell Histiocytosis
NCT05997602Phase 2Recruiting
- Sponsor
- Fosun Pharma
- Start
- Sep 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of luvometinib in Langerhans cell histiocytosis (LCH), sponsored by Fosun Pharma. Started Sep 2023; status: recruiting.
02
Drugs
luvometinib
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT05997602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05997602.